Artiva Biotherapeutics (NASDAQ:ARTV) Earns “Buy” Rating from Needham & Company LLC

Artiva Biotherapeutics (NASDAQ:ARTV)‘s stock had its “buy” rating reiterated by stock analysts at Needham & Company LLC in a report issued on Monday,Benzinga reports. They presently have a $18.00 price target on the stock. Needham & Company LLC’s price target would suggest a potential upside of 66.67% from the company’s current price.

A number of other research analysts have also commented on the company. Wall Street Zen lowered Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, April 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Friday, April 24th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $18.67.

Artiva Biotherapeutics Stock Performance

Shares of ARTV opened at $10.80 on Monday. The firm has a market capitalization of $266.98 million, a price-to-earnings ratio of -3.16 and a beta of 2.86. The business’s fifty day moving average price is $7.17 and its two-hundred day moving average price is $5.18. Artiva Biotherapeutics has a 52 week low of $1.47 and a 52 week high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its quarterly earnings data on Tuesday, March 10th. The company reported ($0.84) EPS for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.03. As a group, research analysts forecast that Artiva Biotherapeutics will post -3.33 EPS for the current year.

Institutional Trading of Artiva Biotherapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Citadel Advisors LLC raised its stake in Artiva Biotherapeutics by 419.3% during the 3rd quarter. Citadel Advisors LLC now owns 798,397 shares of the company’s stock worth $2,291,000 after buying an additional 644,658 shares during the period. BNP Paribas Financial Markets raised its stake in Artiva Biotherapeutics by 14,463.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock worth $340,000 after buying an additional 117,733 shares during the period. Renaissance Technologies LLC raised its stake in Artiva Biotherapeutics by 46.8% during the 4th quarter. Renaissance Technologies LLC now owns 116,200 shares of the company’s stock worth $498,000 after buying an additional 37,053 shares during the period. Marshall Wace LLP acquired a new stake in shares of Artiva Biotherapeutics in the 4th quarter valued at about $341,000. Finally, Jane Street Group LLC acquired a new stake in shares of Artiva Biotherapeutics in the 2nd quarter valued at about $67,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.